- ￥1700 - 4000
- GeneTex
- 美国
- GTX135357
- 2025年07月13日
- WB, ICC/IF, IHC-P, IHC-Fr, FACS, IP, ELISA, Blocking, IHC, Sandwich ELISA, IHC-P (cell pellet)
- Rabbit
- SARS Coronavirus, SARS Coronavirus 2
企业认证
相关产品推荐更多 >
![Progesterone Receptor antibody [PR500]](https://img1.dxycdn.com/2022/0328/140/0526099445601700453-14.jpg!wh200)
![AMPK alpha 1 antibody [9G3]](https://img1.dxycdn.com/2022/0328/948/9138941853029600453-14.jpg!wh200)
![VEGF Receptor 1 antibody [3D10]](https://img1.dxycdn.com/2022/0328/311/0868934003667500453-14.jpg!wh200)
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Full length SARS-CoV-2 (COVID-19) nucleocapsid Recombinant protein. (SARS-CoV-2 (strain Wuhan-Hu-1))
- 亚型：
IgG
- 形态：
Liquid
- 保存条件：
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
- 克隆性：
Polyclonal
- 标记物：
Unconjugated
- 适应物种：
SARS Coronavirus, SARS Coronavirus 2
- 保质期：
12 months from the shipping date of the product.
- 抗原来源：
SARS Coronavirus 2
- 目录编号：
GTX135357
- 级别：
Primary Antibodies
- 库存：
Available
- 供应商：
GeneTex
- 宿主：
Rabbit
- 应用范围：
WB, ICC/IF, IHC-P, IHC-Fr, FACS, IP, ELISA, Blocking, IHC, Sandwich ELISA, IHC-P (cell pellet)
- 浓度：
0.33 mg/ml (Please refer to the vial label for the specific concentration.)
- 靶点：
This antibody detects SARS-CoV-2 nucleocapsid protein. Our internal testing indicates cross-reactivity with SARS-CoV nucleocapsid protein, but not with MERS-CoV nucleocapsid protein.
- 抗体英文名：
SARS-CoV-2 (COVID-19) Nucleocapsid antibody
- 抗体名：
SARS-CoV-2 (COVID-19) Nucleocapsid 抗体
- 规格：
100 μl/25 μl
| 规格： | 100 μl | 产品价格： | ￥4000.0 |
|---|---|---|---|
| 规格： | 25 μl | 产品价格： | ￥1700.0 |
Sandwich ELISA detection of recombinant full-length SARS-CoV-2 (COVID-19) nucleocapsid protein (GTX135357-pro) using GTX135357 as capture antibody at concentration of 5 μg/mL and GTX632269 as detection antibody at concentration of 1 μg/mL. Mouse IgG antibody (HRP) (GTX213111-01) was diluted at 1:10000 and used to detect the primary antibody.
Indirect ELISA analysis was performed by coating plate with 50 μL of recombinant full-length SARS-CoV-2 (COVID-19) nucleocapsid protein (GTX135357-pro) at concentrations ranging from 0.0625 μg/mL to 4 μg/mL. The coated protein is detected with SARS-CoV-2 (COVID-19) nucleocapsid antibody (GTX135357) at 1 μg/mL. Rabbit IgG antibody (HRP) (GTX213110-01) was diluted at 1:10000 and used to detect the primary antibody.
SARS-CoV-2 (COVID-19) nucleocapsid antibody (GTX135357) detects SARS-CoV-2 (COVID-19) nucleocapsid by flow cytometry analysis.
Sample: Vero E6 cells infected with SARS-CoV-2.
Black: Uninfected Vero E6 cells was used as a control.
Red: SARS-CoV-2 (COVID-19) nucleocapsid antibody (GTX135357) dilution: 1:100.
Non-transfected (–) and transfected (+) 293T whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with SARS-CoV-2 (COVID-19) nucleocapsid antibody (GTX135357) diluted at 1:5000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.
SARS-CoV-2 (COVID-19) nucleocapsid antibody detects SARS-CoV-2 (COVID-19) nucleocapsid protein by immunohistochemical analysis.
Sample: Paraffin-embedded SARS-CoV-2 (COVID-19) Nucleocapsid FFPE Cell Pellet Block.
Green: SARS-CoV-2 (COVID-19) nucleocapsid stained by SARS-CoV-2 (COVID-19) nucleocapsid antibody (GTX135357) diluted at 1:1000.
Red: SARS-CoV / SARS-CoV-2 (COVID-19) nucleocapsid stained by SARS-CoV / SARS-CoV-2 (COVID-19) nucleocapsid antibody [6H3] (GTX632269) diluted at 1:1000.
Blue: Fluoroshield with DAPI (GTX30920).
Antigen Retrieval: Citrate buffer, pH 6.0, 15 min
Immunoprecipitation of SARS-CoV-2 (COVID-19) nucleocapsid protein from SARS-CoV-2 (2019-nCoV) NP-transfected 293T whole cell extract using 1 μg of SARS-CoV-2 (COVID-19) nucleocapsid antibody (GTX135357).
Western blot analysis was performed using SARS-CoV-2 (COVID-19) nucleocapsid antibody (GTX135357).
EasyBlot HRP-conjugated anti rabbit IgG antibody (GTX221666-01).
Non-transfected (–) and transfected (+) 293T whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with SARS-CoV-2 (COVID-19) nucleocapsid antibody (GTX135357) diluted at 1:5000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.
SARS-CoV-2 (COVID-19) nucleocapsid antibody detects SARS-CoV-2 (COVID-19) nucleocapsid protein by immunohistochemical analysis.
Sample: Mock (GTX435670) and SARS-CoV-2 (COVID-19) Nucleocapsid transfected 293T cell FFPE Cell Pellet Block (GTX435641).
Green: SARS-CoV-2 (COVID-19) nucleocapsid stained by SARS-CoV-2 (COVID-19) nucleocapsid antibody (GTX135357) diluted at 1:1000.
Blue: Fluoroshield with DAPI (GTX30920).
Antigen Retrieval: Citrate buffer, pH 6.0, 15 min
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Nguyen LC et al., mBio 2022 (PMID:36125275)
Nguyen LC et al., bioRxiv 2022 (PMID:35821981)
Suryawanshi RK et al., Nature 2022 (PMID:35584773)
Yeh CT et al., Biomedicines 2022 (PMID:36359294)
Ahmed-Belkacem A et al., Viruses 2022 (PMID:36146735)
Zhang Z et al., Nat Commun 2022 (PMID:35931673)
L?pez-Mu?oz AD et al., Sci Adv 2022 (PMID:35921414)
Cheng Y et al., ACS Nano 2022 (PMID:35878004)
Chen IP et al., Cell Rep 2022 (PMID:35839775)
Gregoire C et al., Immunity 2022 (PMID:35768001)
Zhang Q et al., J Exp Med 2022 (PMID:35708626)
Anne Zebitz Eriksen et al., STAR Protoc 2022 (PMID:35664254)
Rumi Ueha et al., Front Cell Infect Microbiol 2022 (PMID:35770069)
Qian Wang et al., Cell Rep 2022 (PMID:35658975)
Anthony Fern?ndez-Casta?eda et al., Cell 2022 (PMID:35768006)
Christian Setz et al., Int J Mol Sci 2022 (PMID:35743273)
Ittipat Meewan et al., Pharmaceuticals (Basel) 2022 (PMID:35745663)
Drake M Mellott et al., bioRxiv 2020 (PMID:33140046)
Xiaoquan Li et al., bioRxiv 2020 (PMID:33140048)
Sara Schumann et al., Int J Mol Sci 2020 (PMID:33233817)
Zijun Wang et al., Sci Transl Med 2021 (PMID:33288661)
William M Schneider et al., Cell 2021 (PMID:33382968)
Matthew Gagne et al., Cell 2022 (PMID:35447072)
Zijun Wang et al., Immunity 2022 (PMID:35447092)
Mengfei Chen et al., bioRxiv 2022 (PMID:35441175)
Emiel Vanhulle et al., Biotechniques 2022 (PMID:35445605)
Emiel Vanhulle et al., Antiviral Res 2022 (PMID:35595082)
Paul Bastard et al., Sci Immunol 2021 (PMID:34413139)
Sung-Chan Wei et al., Front Immunol 2021 (PMID:35003088)
Dapeng Li et al., bioRxiv 2022 (PMID:35118474)
Anthony Fern?ndez-Casta?eda et al., bioRxiv 2022 (PMID:35043113)
Giuseppe Palladino et al., Mol Ther Methods Clin Dev 2022 (PMID:35345593)
Valeria Garcia-Flores et al., Nat Commun 2022 (PMID:35042863)
Zijun Wang et al., bioRxiv 2022 (PMID:35132412)
Chi-Ju Hsu et al., Microbiol Spectr 2022 (PMID:35196799)
Setu M Vora et al., Proc Natl Acad Sci U S A 2022 (PMID:35149555)
Yasuo Ariumi et al., J Virol 2022 (PMID:35107372)
Patrick Madden et al., Res Sq 2022 (PMID:35411346)
H-Heinrich Hoffmann et al., Cell Host Microbe 2021 (PMID:33357464)
E A Rosado-Olivieri et al., bioRxiv 2021 (PMID:33442697)
Alice Lu-Culligan et al., Med (N Y) 2021 (PMID:33969332)
Barbara Knoblach et al., Mol Biol Cell 2021 (PMID:34010015)
Xiaoquan Li et al., PLoS Pathog 2021 (PMID:34478458)
L?pez-Mu?oz AD et al., bioRxiv 2021 (PMID:34931195)
Piscotta FJ et al., mSphere 2021 (PMID:34851166)
Madden PJ et al., bioRxiv 2022 (PMID:35262081)
Wagner TR et al., EMBO Rep 2021 (PMID:34927793)
Yewdell J et al., Res Sq 2021 (PMID:34931184)
Gagne M et al., Cell 2021 (PMID:34921774)
Saiz ML et al., Clin Epigenetics 2021 (PMID:34635175)
Peng YC et al., Diagnostics (Basel) 2021 (PMID:34679536)
Kmiec D et al., PLoS Pathog 2021 (PMID:34695163)
Carapito R et al., Sci Transl Med 2021 (PMID:34698500)
Cantwell AM et al., J Virol 2021 (PMID:34319784)
Corbett KS et al., Nat Immunol 2021 (PMID:34417590)
Corbett KS et al., Science 2021 (PMID:34529476)
Francica JR et al., Sci Transl Med 2021 (PMID:34315825)
Junqueira C et al., Res Sq 2021 (PMID:34401873)
Verma R et al., mSystems 2021 (PMID:34254825)
Hoffmann HH et al., bioRxiv 2020 (PMID:33052348)
Mor M et al., bioRxiv 2020 (PMID:33052341)
Wang Z et al., bioRxiv 2020 (PMID:32935095)
Eriksen A.Z. et al., Cell Stem Cell 2021 (PMID:34022129)
DiPiazza A.T. et al., Immunity 2021 (PMID:34270939)
Li D. et al., Cell 2021 (PMID:34242577)
Wang Z et al., Nature 2021 (PMID:34126625)
Sci Immunol 2021;6(59)
Schmidt F et al., J Exp Med 2020 (PMID:32692348)
Sukhikh G et al., Viruses 2021 (PMID:33801923)
Saunders KO et al., Nature 2021 (PMID:33971664)
Park SH et al., PLoS Pathog 2021 (PMID:34003853)
Schmidt F et al., bioRxiv 2020 (PMID:32577658)
Mellott DM et al., ACS Chem Biol 2021 (PMID:33787221)
Hoffmann H. et al., Cell 2021 (PMID:33338421)
Caroline B Plescia et al., J Biol Chem 2021 (PMID:33214224)
Rosado-Olivieri E. et al., Cell 2021 (Epub)
Li J et al., ACS Sens 2021 (PMID:33629833)
Meyer M et al., bioRxiv 2021 (PMID:33532780)
Lu-Culligan A et al., medRxiv 2021 (PMID:33532791)
Sukhikh G et al., Viruses 2021;13(3)
Mor M et al., PLoS Pathog 2021 (PMID:33571304)
William M Schneider et al., Cell 2020 (PMID:33052332)
Robbiani DF et al., Nature 2020 (PMID:32555388)
Thomas Mandel Clausen et al., Cell 2020 (PMID:32970989)
Robbiani DF et al., bioRxiv 2020 (PMID:32511384)
Kizzmekia S Corbett et al., N Engl J Med . 2020 (PMID:32722908)
Davide F. Robbiani et al., bioRxiv 2020 (Epub)
Alena Reguzova et al., Research Square 2023
Carlin AF et al., Open Forum Infect Dis 2023 (PMID:37096144)
Hastie KM et al., Cell Rep 2023 (PMID:37083327)
NK Routhu et al., Sci Immunol 2023 (PMID:37191508)
MACSQuant Tyto 细胞分选仪助力开发 COVID-19 新疗法
丹麦奥胡斯大学医院传染病研究部门，Dr. Mariane H. Schleimann 与其团队现在正大量参与对新型冠状病毒(SARS-CoV-2)的研究。正如全世界的情况一样，迫切需要找到针对 COVID-19 有效的疫苗，以及治疗方法，这激发了许多基础研究、转化和临床组织共同投入到 COVID-19 研究中。 以下是由美天旎生物技术与 Dr. Mariane H. Schleimann 根据其对 COVID-19 研究进行的访谈: 1. Dr. Mariane H
COVID-19 infection. Nature Scientifc Reports 2:MacMullan,MA et al. (2020) ELISA detection of SARS-CoV-2 antibodies in saliva. Nature Scientifc Reports 3:Hettegger,P et al. (2019) High similarity of IgG antibody profles in blood and saliva opens
高福院士团队 Lancet 发文：北京 COVID-19 病例分析表明，疫情爆发期间未出现新变种
城到动态清零政策，精准防控，阻止了新冠病毒的传播。随着 Omicron 亚变体致病性的减弱、疫苗接种的普及和防控经验的积累，2022 年 11 月中旬，中国调整和优化了预防和控制策略。 中国在调整防控政策后，疫情在中国的快速传播引起了世界的关注，并引发了人们对此次疫情是否会驱动新 SARS-CoV-2 变体出现的担忧。因此，对流行的 SARS-CoV-2 变体进行全面的时空研究，对于全球应对当前的 COVID-19 大流行至关重要。北京拥有常住人口 2100 万，在政策调整后初期成为中国病例
技术资料暂无技术资料 索取技术资料
